UK Issues New Guidance on Pediatric Trials
Children and young people should routinely be offered the opportunity to participate in and to benefit from medical research.
Children and young people should routinely be offered the opportunity to participate in and to benefit from medical research, according to updated guidance from the UK Royal College of Pediatrics and Child Health.
The guidelines provide updated practical information on ethical issues in relation to research involving children, aimed at research councils. It reflects many of the changes that have taken place with regards to EU regulations over the last 14 years. The key principles include:
- Risk. Research should ideally carry no greater than minimal or low risk. However, research that involves greater than minimal risk may be acceptable if the interventions involve diagnostic procedures or treatments that are important for the individual child.
- Assent or consent. In most instances, the child's assent or consent should be underpinned by parent consent. However, in the context of research, dissent should be respected, even if parent consent continues.
- Sedation. Researchers must justify the use of sedation, and provide evidence that appropriate monitoring will be in place during the procedure, and that they possess the necessary competencies and skills to carry out the procedures, and to deal immediately with any adverse effects.
- Rewards. The nature of any token of thanks should be in proportion with the age of the child, approved by the research ethics committee, and made clear in the parent/patient information sheets.
“Children require protection, but this should not preclude the claim of other rights, including the right to the highest standard of healthcare, to be informed, express their views, and influence decisions made about them,” said lead author Neena Modi, MD, Professor of Neonatal Medicine at Imperial College London. “The more robust research we can conduct, the greater the likelihood of developing new treatments and procedures that will greatly improve healthcare for children and young people.”
The guidelines also emphasize the importance of involving children, young people and parents in all aspects of medical research—from prioritization to development and dissemination. Overall, they reflect current regulations and should help researchers make the right decisions about child health research in the best interest of the child, she added.
The guidance was published in an online article posted on June 9 by
Archives of Disease in Childhood
. To access the full article,
click here
.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
